Have Investors Already Priced In Healthcare Growth For Neothetics Inc (NEOT)?
Neothetics Inc (NASDAQ:NEOT), a USD$17.15M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronic diseases. Healthcare analysts are forecasting for the entire industry, a relatively muted growth of 6.42% in the upcoming year, and a whopping growth of 43.65% over the next couple of years. Not surprisingly, this rate is more than double the growth rate of the US stock market as a whole. Below, I will examine the sector growth prospects, as well as evaluate whether NEOT is lagging or leading in the industry. View our latest analysis for Neothetics
What’s the catalyst for NEOT’s sector growth?
Data analytics and other technology-enabled approaches are creating opportunities for innovations, however, stakeholders have been challenged to keep abreast of this structural shift while under pressure to cut costs. In the past year, the industry delivered negative growth of -60.80%, underperforming the US market growth of 4.49%. NEOT leads the pack with its impressive earnings growth of 71.49% over the past year. This proven growth may make NEOT a more expensive stock relative to its peers.
Is NEOT and the sector relatively cheap?
Biotech companies are typically trading at a PE of 31x, higher than the rest of the US stock market PE of 22x. This means the industry, on average, is relatively overvalued compared to the wider market. However, the industry did return a higher 15.86% compared to the market’s 9.99%, which may be indicative of past tailwinds. Since NEOT’s earnings doesn’t seem to reflect its true value, its PE ratio isn’t very useful. A loose alternative to gauge NEOT’s value is to assume the stock should be relatively in-line with its industry.
What this means for you:
Are you a shareholder? NEOT recently delivered an industry-beating growth rate in earnings, which is a positive for shareholders. If you’re bullish on the stock and well-diversified by industry, you may decide to hold onto NEOT as part of your portfolio. However, if you’re relatively concentrated in biotech, you may want to value NEOT based on its cash flows to determine if it is overpriced based on its current growth outlook.
Are you a potential investor? If NEOT has been on your watchlist for a while, now may be the time to enter into the stock, if you like its ability to deliver growth and are not highly concentrated in the biotech industry. Before you make a decision on the stock, take a look at NEOT’s cash flows and assess whether the stock is trading at a fair price.
For a deeper dive into Neothetics’s stock, take a look at the company’s latest free analysis report to find out more on its financial health and other fundamentals. Interested in other healthcare stocks instead? Use our free playform to see my list of over 1000 other healthcare companies trading on the market.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
